Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel

BACKGROUND: A subset of triple-negative breast cancers (TNBCs) have homologous recombination deficiency with upregulation of compensatory DNA repair pathways. PIKTOR, a combination of TAK-228 (TORC1/2 inhibitor) and TAK-117 (PI3Kα inhibitor), is hypothesized to increase genomic instability and incre...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Jessica D., Nguyen, Tuong Vi V., Levin, Maren K., Blas, Page E., Williams, Heather L., Rodriguez, Esther San Roman, Briones, Natalia, Mueller, Claudius, Selleck, William, Moore, Sarah, Zismann, Victoria L., Hendricks, William P.D., Espina, Virginia, O’Shaughnessy, Joyce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369813/
https://www.ncbi.nlm.nih.gov/pubmed/37491309
http://dx.doi.org/10.1186/s40364-023-00511-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369813/
https://www.ncbi.nlm.nih.gov/pubmed/37491309
http://dx.doi.org/10.1186/s40364-023-00511-7

Ejemplares similares